Serum p-Glycoprotein and Monomeric C-Reactive Protein are Elevated in Takayasu Arteritis.

IF 4.2 2区 医学 Q2 IMMUNOLOGY Journal of Inflammation Research Pub Date : 2024-11-11 eCollection Date: 2024-01-01 DOI:10.2147/JIR.S490958
Darpan Radheshyam Thakare, Kritika Singh, Tooba Qamar, Deeksha Singh, Sandeep Balakrishnan, Upendra Rathore, Neeraj Jain, Manish Ora, Durga Prasanna Misra
{"title":"Serum p-Glycoprotein and Monomeric C-Reactive Protein are Elevated in Takayasu Arteritis.","authors":"Darpan Radheshyam Thakare, Kritika Singh, Tooba Qamar, Deeksha Singh, Sandeep Balakrishnan, Upendra Rathore, Neeraj Jain, Manish Ora, Durga Prasanna Misra","doi":"10.2147/JIR.S490958","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Existing biomarkers including C-reactive protein (CRP) do not adequately distinguish active and inactive TAK. We compared serum p-glycoprotein (p-gp)/Multidrug Resistance Protein 1 (MDR1), monomeric CRP (mCRP), CRP, and mCRP:CRP ratio in Takayasu arteritis (TAK) and healthy controls and their relationship with disease activity.</p><p><strong>Patients and methods: </strong>Serum p-gp mCRP (ELISA) and CRP (nephelometry) were compared between consecutive adults with TAK (>18 years) enrolled from a prospective cohort (n = 92) and healthy controls (n = 29), and between active vs inactive TAK (n = 46 each). In a subset of active immunosuppressive-naïve TAK (n = 29), correlation was assessed between serum p-gp and p-gp expression on circulating T helper lymphocyte populations: overall (CD4+), Th17 (CD4+IL-17+), Th17.1 (CD4+IL-17+IFN-γ+) lymphocytes [normalized to Tregs (CD4+CD25+FoxP3+)]. Changes in serum p-gp, mCRP, CRP, and mCRP:CRP were compared before and after immunosuppression (n = 29). Data was represented using median (Q1-Q3). Receiver operating characteristics (ROC) curves were generated for TAK vs controls, and active vs inactive TAK with serum p-gp, mCRP, CRP, and mCRP:CRP. Multivariable-adjusted linear regression was used to predict active disease with serum p-gp, mCRP, CRP, or mCRP:CRP.</p><p><strong>Results: </strong>Serum p-gp (11.19 vs 8.05 ng/mL), mCRP (1.61 vs 1.25 µg/L), and CRP (5.40 vs 2.1 mg/L) were elevated in TAK vs controls (p <0.05 for all). CRP was higher and mCRP:CRP ratio was lower in active vs inactive TAK (p < 0.001). ROC curves identified moderate prediction for active disease with CRP and inactive disease with serum p-gp (area under ROC curve 0.705 and 0.392, respectively). Multivariable-adjusted linear regression confirmed association of CRP with active disease (p = 0.009) and serum p-gp with inactive disease (p = 0.041). In treatment-naïve TAK, serum p-gp negatively correlated with p-gp+Th17.1 lymphocytes (Spearman's rho=-0.39, p = 0.046). CRP and serum p-gp were significantly lowered following immunosuppressive therapy in treatment-naïve TAK (p < 0.05).</p><p><strong>Conclusion: </strong>Serum p-gp and mCRP are elevated in TAK. Serum p-gp is associated with inactive disease.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"17 ","pages":"8695-8712"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566576/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S490958","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Existing biomarkers including C-reactive protein (CRP) do not adequately distinguish active and inactive TAK. We compared serum p-glycoprotein (p-gp)/Multidrug Resistance Protein 1 (MDR1), monomeric CRP (mCRP), CRP, and mCRP:CRP ratio in Takayasu arteritis (TAK) and healthy controls and their relationship with disease activity.

Patients and methods: Serum p-gp mCRP (ELISA) and CRP (nephelometry) were compared between consecutive adults with TAK (>18 years) enrolled from a prospective cohort (n = 92) and healthy controls (n = 29), and between active vs inactive TAK (n = 46 each). In a subset of active immunosuppressive-naïve TAK (n = 29), correlation was assessed between serum p-gp and p-gp expression on circulating T helper lymphocyte populations: overall (CD4+), Th17 (CD4+IL-17+), Th17.1 (CD4+IL-17+IFN-γ+) lymphocytes [normalized to Tregs (CD4+CD25+FoxP3+)]. Changes in serum p-gp, mCRP, CRP, and mCRP:CRP were compared before and after immunosuppression (n = 29). Data was represented using median (Q1-Q3). Receiver operating characteristics (ROC) curves were generated for TAK vs controls, and active vs inactive TAK with serum p-gp, mCRP, CRP, and mCRP:CRP. Multivariable-adjusted linear regression was used to predict active disease with serum p-gp, mCRP, CRP, or mCRP:CRP.

Results: Serum p-gp (11.19 vs 8.05 ng/mL), mCRP (1.61 vs 1.25 µg/L), and CRP (5.40 vs 2.1 mg/L) were elevated in TAK vs controls (p <0.05 for all). CRP was higher and mCRP:CRP ratio was lower in active vs inactive TAK (p < 0.001). ROC curves identified moderate prediction for active disease with CRP and inactive disease with serum p-gp (area under ROC curve 0.705 and 0.392, respectively). Multivariable-adjusted linear regression confirmed association of CRP with active disease (p = 0.009) and serum p-gp with inactive disease (p = 0.041). In treatment-naïve TAK, serum p-gp negatively correlated with p-gp+Th17.1 lymphocytes (Spearman's rho=-0.39, p = 0.046). CRP and serum p-gp were significantly lowered following immunosuppressive therapy in treatment-naïve TAK (p < 0.05).

Conclusion: Serum p-gp and mCRP are elevated in TAK. Serum p-gp is associated with inactive disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高安动脉炎患者血清对糖蛋白和单聚 C 反应蛋白升高
目的:包括C反应蛋白(CRP)在内的现有生物标志物并不能充分区分活性和非活性TAK。我们比较了高安动脉炎(TAK)和健康对照组的血清 p-糖蛋白(p-gp)/多药抵抗蛋白 1(MDR1)、单体 CRP(mCRP)、CRP 和 mCRP:CRP 比值及其与疾病活动性的关系:比较了前瞻性队列中连续登记的成人TAK患者(大于18岁)(92人)和健康对照组(29人)的血清p-gp mCRP(ELISA)和CRP(肾谱测定法),以及活动性TAK和非活动性TAK(各46人)的血清p-gp mCRP(ELISA)和CRP(肾谱测定法)。在活动性免疫抑制-非活动性TAK亚组(n = 29)中,评估了血清p-gp与循环T辅助淋巴细胞群p-gp表达之间的相关性:总体(CD4+)、Th17(CD4+IL-17+)、Th17.1(CD4+IL-17+IFN-γ+)淋巴细胞[与Tregs(CD4+CD25+FoxP3+)归一化]。比较免疫抑制前后血清 p-gp、mCRP、CRP 和 mCRP:CRP 的变化(n = 29)。数据用中位数(Q1-Q3)表示。根据血清p-gp、mCRP、CRP和mCRP:CRP,生成了TAK与对照组、活动性TAK与非活动性TAK的接收者操作特征曲线(ROC)。使用多变量调整线性回归预测血清p-gp、mCRP、CRP或mCRP:CRP的活动性疾病:结果:TAK 与对照组相比,血清 p-gp(11.19 vs 8.05 ng/mL)、mCRP(1.61 vs 1.25 µg/L)和 CRP(5.40 vs 2.1 mg/L)均升高(p 结论:血清 p-gp、mCRP 和 CRP 均高于对照组:TAK患者血清p-gp和mCRP升高。血清p-gp与非活动性疾病相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Inflammation Research
Journal of Inflammation Research Immunology and Microbiology-Immunology
CiteScore
6.10
自引率
2.20%
发文量
658
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.
期刊最新文献
Chronic Inflammation and Age-Related Hearing: Based on Mendelian Randomization. Norisoboldine Reduces Arthritis Severity by Attenuating Inflammation, Oxidative Stress, and Extracellular Matrix Degradation in a Rat Model of Rheumatoid Arthritis. Predictive Value of dsDNA and Nucleosomes as Neutrophil Extracellular Traps-Related Biomarkers for COVID-19 in Older Patients. Cardamonin Attenuates Myocardial Ischemia/Reperfusion-Induced Ferroptosis Through Promoting STAT3 Signaling. Serpin B9 is Highly Expressed in Lung Adenocarcinoma and is Associated with Progression-Free Survival.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1